The FDA has approved a supplemental new drug application submitted by Otsuka Pharmaceutical and Bristol-Myers Squibb (BMS) for Abilify to treat manic and ...
ABILIFY (aripiprazole) has been approved by the FDA for patients 10 to 17 years old for the treatment of acute manic and mixed episodes of Bipolar I ...
all 2 news articles
ABILIFY has been approved for the acute and maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic ...
Abilify, developed by Otsuka jointly with Bristol-Myers Squibb, was approved by the Food and Drug Administration (FDA) for treatment of acute manic and ...
NEW YORK (Associated Press) - Bristol-Myers Squibb Co. and Japanese partner Otsuka Pharmaceutical Co. said Friday that federal regulators approved Abilify ...
By Anna Boyd The US Food and Drug Administration cleared Abilify (aripiprazole) Friday for treatment of bipolar disorder in adolescents, the Wall Street ...
Otsuka Pharmaceutical Co. and Bristol-Myers Squibb Co. said the Food and Drug Administration approved the supplemental new-drug application for Abilify to ...
The latest studies on Abilify were carried out for a period of four weeks on children aged between 10 and 17. The study gave amazing results about the ...
s antipsychotic medicine Abilify was cleared by US regulators to treat bipolar disorder in children as young as 10, according to a report in Bloomberg News. ...